Explore articles, research, and perspectives from the International Perfusion Association.
This study aimed to compare the release of brain injury biomarkers between standard and high cardiopulmonary bypass (CPB) flow rates during elective cardiac surgery.
This survey examines the readiness of on-call and emergency operation rooms for perfusion-related procedures during urgent situations in cardiac surgery. Data from 236 healthcare
This study investigates the effects of haemoadsorption (HA) therapy on inflammatory markers and renal damage indices during cardiopulmonary bypass (CPB) and the early postoperative
The first annual report of the Perfusion Measures and Outcomes (PERForm) registry details patient characteristics and cardiopulmonary bypass (CPB) practices from 2019 to 2022
This study outlines the transformation of perfusion clinical education from a teacher-centered to a student-centered model. By incorporating reflective practice, self-evaluation, and problem-based learning,
This article explores the utilization of venovenous bypass (VVB) in liver transplantation (LT), highlighting its benefits, efficacy, and safety. Although VVB helps maintain hemodynamic
This study investigated the efficacy of intravenous amino acids in reducing acute kidney injury (AKI) in patients undergoing cardiac surgery. A total of 3511
The “Easy Flow Cardiopulmonary Bypass Simulation Model” offers a cost-effective, innovative approach to perfusion training using standard CPB equipment found in operating rooms. Unique
A new technique for accessing the mitral valve via the left anterior minithoracotomy has been developed for patients requiring both mitral valve surgery and
This study evaluates the FUWAI-SAVE system, a modified low-priming cardiopulmonary bypass (CPB) system, in reducing perioperative blood transfusions in adult patients undergoing cardiac surgery
The shortage of suitable lung donors remains a significant challenge in lung transplantation. While brain-death donors (DBD) currently provide most lung allografts, only 20%
On May 8, 2024, the FDA warned healthcare providers about ongoing safety concerns with Getinge/Maquet cardiovascular devices, specifically the Cardiosave Hybrid and Rescue IABP
